NOCIL LIMITED
NOCIL · General/Diversified · NSE
₹172
Current Market Price
Fair Value (DCF)
₹69
Margin of Safety
-60.0%
Updated 1d ago
YieldIQ Score
18/100
Piotroski F-Score
4/9
Economic Moat
None
Confidence
45%
ROE
—
Debt/Equity
0.01
WACC
11.1%
Market Cap
₹2,878 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
6.1%
Return on capital employed
EV / EBITDA
25.0×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
64.8×
EBIT covers interest
Current Ratio
5.82×
Short-term liquidity
Asset Turnover
0.67×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-4.2%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹172.3
Bear case
₹47.07
MoS -266.1%
Base case
₹68.93
MoS -150.0%
Bull case
₹97.19
MoS -77.3%
Ratio Trends
NOCIL · last 9 annual periods
ROE
5.8%
ROCE
9.6%
Operating Margin
—
Debt / Equity
0.01×
PE
121.9×
EV / EBITDA
13.2×
Historical Financials
NOCIL · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹925 Cr | ₹1571 Cr | ₹393 Cr | ₹357 Cr | ₹1372 Cr | +10.4% |
| EBITDA | — | ₹290 Cr | ₹259 Cr | ₹234 Cr | ₹170 Cr | -12.6% |
| EBIT | ₹108 Cr | ₹242 Cr | ₹38.8 Cr | ₹56.0 Cr | — | -15.2% |
| PAT | ₹88.4 Cr | ₹176 Cr | ₹28.3 Cr | ₹41.5 Cr | ₹103 Cr | +3.9% |
| EPS (diluted) | ₹5.32 | ₹10.55 | ₹1.70 | ₹2.48 | — | -17.4% |
| CFO | ₹93.6 Cr | ₹-30.2 Cr | ₹282 Cr | ₹201 Cr | ₹25.6 Cr | -27.7% |
| CapEx | — | — | — | — | ₹-123 Cr | — |
| FCF | — | — | — | — | ₹-97.6 Cr | — |
| Total Assets | — | ₹1831 Cr | ₹1857 Cr | ₹2015 Cr | ₹2057 Cr | +3.0% |
| Total Debt | — | — | ₹0.0 Cr | ₹0.0 Cr | ₹10.3 Cr | — |
| Shareholders' Equity | — | — | ₹1552 Cr | ₹1699 Cr | ₹1762 Cr | +3.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
NOCIL vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| JUBLCPL JUBILANT AGRI N CON PRO L | -14.0% | 57 | Fairly valued | 27.0% | — |
| ROSSARI ROSSARI BIOTECH LIMITED | -11.5% | 51 | Fairly valued | 11.5% | — |
| POLYPLEX POLYPLEX | — | — | Pending | 3.4% | — |
| TATVA TATVA | — | — | Pending | 0.8% | — |
| KIRIINDUS KIRIINDUS | — | — | Pending | 8.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for NOCIL in the last 10 years.
AI Analysis Summary
NOCIL LIMITED appears overvalued by 60.0%, with a standout strength in its low debt-to-equity ratio of 0.01, but a concern is its low 3-year revenue CAGR of 0.0%.
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of NOCIL →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for NOCIL →
Compare
Head-to-head with peers
Compare NOCIL side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse NOCILNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.